Dvx Inc. Reports Unaudited Non-Consolidated Financial Results for the Three Months Ended June 30, 2019; Provides Non-Consolidated Financial Guidance for the Six Months Ended September 30, 2019 and Full Year Ending March 31, 2020; Provides Dividend Guidance for the Year Ended March 31, 2020
July 29, 2019
Share
DVx Inc. reported unaudited non-consolidated financial results for the three months ended June 30, 2019. For the quarter, the company reported net sales of JPY 10,864 million against JPY 10,012 million a year ago. Operating profit was JPY 150 million against JPY 261 million a year ago. Ordinary profit was JPY 157 million against JPY 270 million a year ago. Profit was JPY 106 million against JPY 235 million a year ago. Earnings per share were JPY 9.85 against JPY 20.93 a year ago.
The company provided non-consolidated financial guidance for the six months ended September 30, 2019 and full year ending March 31, 2020. For the six months, the company expects net sales of JPY 21,797 million, operating profit of JPY 310 million, ordinary profit of JPY 310 million, Profit of JPY 207 million and earnings per share of JPY 19.20.
For the full year, the company expects net sales of JPY 42,948 million, operating profit of JPY 871 million, ordinary profit of JPY 871 million, Profit of JPY 580 million and earnings per share of JPY 53.59.
The company provided dividend guidance for the year ended March 31, 2020. For the year, the company expects dividend of JPY 24 per share.
DVx Inc. is a Japan-based company mainly engaged in the sale of medical equipment for circulatory system diseases. The Company operates in two business segments. The Arrhythmia segment mainly sells cardiac pacemakers, implantable cardioverter-defibrillators (ICDs), electrode catheters and ablation catheters. The Ischemia segment is engaged in the import and sale of automated contrast medium injectors under the name ACIST, excimer laser angioplasty systems, as well as sale of coronary artery stent products as agency business. The others business is engaged in the sale of neurosurgical products, general surgery related products, gastrointestinal related products, radiation protection supplies, among others.
Dvx Inc. Reports Unaudited Non-Consolidated Financial Results for the Three Months Ended June 30, 2019; Provides Non-Consolidated Financial Guidance for the Six Months Ended September 30, 2019 and Full Year Ending March 31, 2020; Provides Dividend Guidance for the Year Ended March 31, 2020
DVX INC. 
